Co-hosted by PATH and the Kenya Ministry of Health, the Evidence to Practice workshop involved more than 175 participants from 20+ countries, including ministry of health representatives, implementing partners, and donors.
Workshop participants shared the latest evidence regarding DMPA-SC* (brand name Sayana® Press) and self-injection, and developed country action plans. In addition, two regional DMPA-SC Learning and Action Networks—one Anglophone and one Francophone—were launched under the DMPA-SC Access Collaborative to sustain connections and facilitate evidence-based progress across countries.
Overview and resources
- DMPA-SC: Evidence to Practice meeting report (English, Français, Portugues)
- DMPA-SC: Evidence to Practice meeting agenda (English, Français, Portugues)
- Presentation: Review of DMPA-SC and how it can increase access
- Resources: A list of references about subcutaneous DMPA (from the Advocacy Pack for Subcutaneous DMPA)
Effective delivery of DMPA-SC
- The Coming-of-Age of Subcutaneous Injectable Contraception (2018)
- Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries (2018)
- Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal (2014)
- Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects (2018)
Self-injection: Acceptability, feasibility, and effectiveness
- DMPA self-administration can improve contraceptive access, continuation, and autonomy (2018)
- A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection (2017)
- Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study (2017)
- Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial (2018)
- Client and provider experiences with self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Malawi (2018)
- Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda
- Costs of administering injectable contraceptives through health workers and self-injection: Evidence from Burkina Faso, Uganda, and Senegal (2018)
“ We have moved beyond the period of pilots and studies—countries need to move to planning for ambitious scale up and use a cascade approach to train providers swiftly. ”— Evidence to Practice workshop participant
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate.
Sayana Press is a registered trademark of Pfizer Inc. Uniject is a trademark of BD.